USFDA approves COVID antiviral pill molnupiravir for emergency use

The USFDA also said the drug should be given for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. The regulatory agency said molnupiravir should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32sa12T
via IFTTT